Why your heart still risks failure even if your cholesterol is low
Role of Residual Inflammation as a Risk Factor Across Cardiovascular-Kidney-Metabolic (CKM) Syndrome: Unpacking the Burden in People with Type 2 Diabetes
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Even when diabetes patients take pills to lower sugar and cholesterol, their heart and kidneys can still get damaged because of hidden body inflammation. New medicines that calm this inflammation can stop more heart attacks and kidney failures.
Surprising Findings
SGLT2 inhibitors reduce heart failure hospitalizations by 30–35% and cardiovascular death by up to 38%—even before blood sugar improves.
Everyone assumed these drugs worked by lowering glucose; this shows they protect the heart through inflammation and fluid shifts, not sugar control.
Practical Takeaways
Ask your doctor for an hsCRP blood test—if it’s above 2 mg/L, discuss whether colchicine, an SGLT2 inhibitor, or GLP-1 RA might reduce your heart/kidney risk.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Even when diabetes patients take pills to lower sugar and cholesterol, their heart and kidneys can still get damaged because of hidden body inflammation. New medicines that calm this inflammation can stop more heart attacks and kidney failures.
Surprising Findings
SGLT2 inhibitors reduce heart failure hospitalizations by 30–35% and cardiovascular death by up to 38%—even before blood sugar improves.
Everyone assumed these drugs worked by lowering glucose; this shows they protect the heart through inflammation and fluid shifts, not sugar control.
Practical Takeaways
Ask your doctor for an hsCRP blood test—if it’s above 2 mg/L, discuss whether colchicine, an SGLT2 inhibitor, or GLP-1 RA might reduce your heart/kidney risk.
Publication
Journal
Diabetes Therapy
Year
2025
Authors
Roya Ghafoury, M. Malek, Faramarz Ismail-Beigi, M. Khamseh
Related Content
Claims (5)
Cardiovascular risk persists despite low LDL cholesterol levels if concomitant metabolic syndrome, hypertension, chronic inflammation, or dysglycemia remain unaddressed.
Even when diabetics take pills to lower their bad cholesterol, if they still have high levels of a blood marker called hsCRP, they’re still at high risk for heart attacks and strokes — meaning inflammation is still hurting them.
A class of diabetes drugs (SGLT2 inhibitors) cuts hospitalizations for heart failure by a third and lowers death risk by nearly 40% — even before blood sugar improves — suggesting they protect the heart in ways beyond lowering sugar.
Diabetes drugs like semaglutide and liraglutide cut heart attacks, strokes, and kidney failure by up to a third — and they work fast, even before blood sugar drops, likely by calming down harmful inflammation in the body.
High blood sugar in diabetes turns on harmful inflammation pathways in the body — damaging blood vessels, kidneys, and the heart — by creating toxic molecules and activating immune switches like NF-κB and NLRP3.